CHEST RADIOLOGY - A CASE OF AZYGOUS LOBE

By Dr Deepu
The lungs are normally divided into five lobes by three main fissures .
 Occasionally, invaginations of the visceral pleura create accessory fissures that separate individual bronchopulmonary segments into accessory lobes .
 An azygos lobe is found in approximately 0.4% of patients . In contrast to other accessory lobes, the azygos lobe does not correspond to a distinct anatomical bronchopulmonary segment .

It forms during embryogenesis when the precursor of the azygos vein fails to migrate to its medial position in the mediastinum, where it normally arches over the origin of the right upper lobe bronchus.
 This gives rise to the following characteristics, which are visible on a standard chest x-ray

: the laterally displaced azygos vein lies between folds of parietal pleura, also referred to as the mesoazygos, where it assumes a characteristic teardrop shape ; the mesoazygos indents the right upper lobe, thereby creating the accessory (azygos) fissure, which is similar in shape to an inverted comma; the fissure delineates the azygos lobe, located superomedially ; laterally, the pleural folds of the mesoazygos separate before reaching the chest wall, resulting in a radiopaque triangular area ; and medially, the tracheobronchial angle appears empty .



 An azygos lobe may be confused with a pathological air space such as a bulla or abscess . In addition, the abnormally located azygos vein may be mistaken for a pulmonary nodule, while a consolidated azygos lobe may be confused with a mass . An understanding of the pathogenesis and characteristic x-ray features of the azygos lobe will enable an accurate diagnosis in most cases .
 If the x-ray findings are equivocal, computed tomography will be diagnostic .

FDA Approves Asthma Indication For COPD Drug.

Food and Drug Administration has approved “the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older.” The drug has already been approved for treating chronic obstructive pulmonary disease (COPD).
  • U.S. FDA latest regulatory authority to approve tiotropium in asthma following authorities in the EU, Japan and other countries
  • Recent GINA 2015 Global Strategy recommends tiotropium by soft mist inhaler as add-on asthma therapy
Ingelheim, Germany, 16. September, 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA® Respimat®(tiotropium bromide) Inhalation Spray for use in the treatment of asthma. It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older. Following previous regulatory approvals, tiotropium by soft-mist inhaler has been included in the recently updated Global Initiative for Asthma report (GINA) 2015 Global Strategy for Asthma Management and Prevention.
Almost one in two patients with asthma still experience symptoms while receiving maintenance therapy, putting them at increased risk of potentially life-threatening asthma exacerbations. Pivotal, Phase III study results show that Spiriva® Respimat® as an add-on treatment to ICS/LABA maintenance therapy:
  • Significantly improves asthma symptoms 
    • patients are 68% more likely to improve asthma control7
  • Significantly reduces the risk of patients having a severe asthma exacerbation by a fifth (21%)
    • reducing the number of patients who experienced a severe asthma exacerbation
The Phase III study results also showed that the safety of SPIRIVA® Respimat® is balanced as compared to placebo.

Pulmonary Specialists Pan Europe To Participate In Project To Develop New Treatments For Cystic Fibrosis, Bronchiectasis

By Dr Deepu
Healio (9/12) reported that “lung specialists across Europe have been recruited to participate in a €50 million project that will develop new treatments for cystic fibrosis and bronchiectasis, according to a press release.” According to Healio, “the inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis consortium...will address the demand for new forms of inhaled antibiotics and the ongoing issue of antimicrobial resistance.”

Reliever Salbutamol Use Appears Linked To Risk Of COPD Exacerbation

By Dr Deepu
Healio (9/12) reported that research indicated that “short-term and long-term use of short-acting beta 2-agonist salbutamol 90 μg appeared associated with increased short- and long-term exacerbation of chronic obstructive pulmonary disease.” The findings were published in BMC Pulmonary Medicine.

CRITICAL CARE Guidelines

       By Dr Deepu
American College of Chest Physicians/La Societe de Reanimation de Langue Francaise Statement on Competence in Critical Care Ultrasonography (April 2009)
NIV in COPD: management of acute type 2 respiratory failure concise guideline Non-invasive ventilation in chronic obstructive pulmonary disorder: management of acute type 2 respiratory failure concise guideline October 2008
The Use of Non-Invasive Ventilation in the management of patients with COPD admitted to hospital with acute type II respiratory failureThe Use of Non-Invasive Ventilation in the management of patients with chronic obstructive pulmonary disease admitted to hospital with acute type II respiratory failure. The full guideline is a joint BTS/RCP London/Intensive Care Society document 2008

Weaning from mechanical ventilation ERS / ATS / ESICM / SCCM / SRLF Statement of the Sixth International Consensus Conference on Intensive Care Medicine 2007